Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.
Javier CortesSara Alsterlind HurvitzJoyce O'ShaughnessySuzette DelalogeHiroji IwataHope S RugoPatrick NevenDheepak KanagavelPatrick CohenGautier PauxSylvaine Cartot-CottonMaya Stefanova-UrenaLaure DeymeJihane AouniBernard SebastienAditya BardiaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The AMEERA-5 study was discontinued on the basis of the recommendation of the data monitoring committee at the interim futility analysis. No new safety signals were identified.
Keyphrases
- phase iii
- epidermal growth factor receptor
- estrogen receptor
- open label
- clinical trial
- double blind
- endothelial cells
- tyrosine kinase
- phase ii
- placebo controlled
- randomized controlled trial
- type diabetes
- machine learning
- electronic health record
- adipose tissue
- big data
- polycystic ovary syndrome
- induced pluripotent stem cells